▲ 患者安全性分析
03
研究结论
本研究结果证实，与索拉非尼相比，多纳非尼治疗延长了不可切除或转移性HCC患者总生存时间 。基于此，多纳非尼或成为晚期HCC一线治疗的新选择 。
【多纳非尼靶向药副作用怎么办 多纳非尼靶向药多少钱一盒】
参考文献
1. Bray F, Ferlay J, Soerjomataram I, et al: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394-424, 2018.
2. Fan JH, Wang JB, Jiang Y, et al: Attributable causes of liver cancer mortality and incidence in China. Asian Pac J Cancer Prev 14:7251-7256, 2013.
3. Qin S, Bai Y, Lim HY, et al: Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol 31:3501-3508, 2013.
4. Cainap C, Qin S, Huang WT, et al: Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma: Results of a randomized phase III trial. J Clin Oncol 33:172-179, 2015.
5. Cheng AL, Kang YK, Chen Z, et al: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25-34, 2009.
6. Kudo M, Finn RS, Qin S, et al: Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial. Lancet 391:1163-1173, 2018.
7. Ren Z, Zhu K, Kang H, et al: Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma. J Clin Oncol 33:894-900, 2015.
8. Llovet JM, Ricci S, Mazzaferro V: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390, 2008.
声明：本资料中涉及的信息仅供参考，请遵从医生或其他医疗卫生专业人士的意见或指导 。
推荐阅读
- 2022年结肠癌靶向药价格一览表 2022年靶向药价格一览表
- 墨者学院实战靶场使用教程
- 彩六靶场怎么换人
- 马拉多纳有什么辉煌战绩
- 马拉多纳拿了多少个世界杯冠军
- 马拉多纳承认：在古巴与两位女性育有3个私生子!
- 迭戈怎么读
- 打靶归来：音乐、歌词、情感
- 打靶归来，温暖往事唤起心底深处
- 成功的靶向制剂应具备四个要素 成功的耙向制剂应具备哪些要素